Fulcrum Therapeutics reported a net loss of $24.8 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities were $297.8 million as of March 31, 2023. They are on track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) during 2H’23 and active discussions continue with the U.S. Food and Drug Administration (FDA) to resolve clinical hold for FTX-6058 in sickle cell disease (SCD).